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Abstract
Background: Septic shock is a life-threatening condition with underlying circulatory and cellular/metabolic abnormalities.
Vitamin C and thiamine are potential candidates for adjunctive therapy; they are expected to improve outcomes based
on recent experimental and clinical research. The aim of the Ascorbic Acid and Thiamine Effect in Septic Shock (ATESS)
trial is to evaluate the effects of early combination therapy with intravenous vitamin C and thiamine on recovery from
organ failure in patients with septic shock.
Methods: This study is a randomized, double-blind, placebo-controlled, multicentre trial in adult patients with septic
shock recruited from six emergency departments in South Korea. Patients will be randomly allocated into the treatment
or control group (1:1 ratio), and we will recruit 116 septic shock patients (58 per group). For the treatment group, vitamin
C (50mg/kg) and thiamine (200mg) will be mixed in 50ml of 0.9% saline and administered intravenously every 12 h for
a total of 48 h. For the placebo group, an identical volume of 0.9% saline will be administered in the same manner. The
primary outcome is the delta Sequential Organ Failure Assessment (SOFA) score (ΔSOFA = initial SOFA at enrolment –
follow-up SOFA after 72 h).
Discussion: This trial will provide valuable evidence about the effectiveness of vitamin C and thiamine therapy for septic
shock. If effective, this therapy might improve survival and become one of the main therapeutic adjuncts for patients with
septic shock.
Trial registration: ClinicalTrials.gov, NCT03756220. Registered on 5 December 2018.
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Background
Septic shock is a life-threatening disease; it is a subset of
sepsis that involves organ dysfunction and profound
underlying circulatory and cellular/metabolic abnormal-
ities that cause death in more than 40% of patients [1,
2]. Not only does septic shock have high mortality, but
the incidence rate is steadily rising due to the aging
population and an increased rate of patients with comor-
bidities, making it very concerning from a public health
perspective [3, 4].
Despite current standard treatments, including
broad-spectrum antibiotics, source control, fluid re-
suscitation, and vasopressors, morbidity and mortality
have remained high, and no adjunctive therapies for
septic shock have been shown to improve survival [5,
6]. Moreover, although appropriate early resuscitation
is applied to patients to improve their haemodynamic
state, metabolic and oxidative stress can persist or
even worsen at the cellular level, causing further
organ dysfunction [1]. Additional interventions to im-
prove patient-centred outcomes for septic shock thus
need to be researched and developed [7].
Vitamin C and thiamine are soluble vitamins that are
essential to human bodies. A deficiency can result in se-
vere symptoms, including shock, cardiac failure, and
central nervous system disorders [8]. Patients in septic
shock show vitamin C and thiamine depletion, which
can further aggravate septic shock [9, 10].
Vitamin C is a well-known antioxidant that is required
as a cofactor/co-substrate for the biosynthesis of colla-
gen, neurotransmitters, endogenous catecholamines,
vasopressin, and cortisol [11]. Vitamin C enhances the
synthesis of endogenous norepinephrine and vasopressin
and increases adrenergic sensitivity [8, 12]. In animal
and cell-based studies of sepsis, vitamin C acted as an
antioxidant defence substance, reducing levels of reactive
oxygen species and reactive nitrogen species and im-
proving microcirculation by limiting oxidative injury and
endothelial barrier disruption [13–17]. Vitamin C also
has anti-inflammatory effects and plays a role in enhan-
cing immune functions [8, 18].
Thiamine is a cofactor that acts on enzymes essential
for glucose metabolism, the generation of adenosine tri-
phosphate, and the production of nicotinamide adenine
dinucleotide phosphate [19]. Thiamine deficiency causes
bioenergetic failure, increases oxidative stress and cell
injury, and accelerates organ failure, including brain dys-
function through neuronal injury [10, 20]. Thiamine ad-
ministration to assist the metabolisms of patients in
septic shock might be reasonable because of its acute
consumption in the hypermetabolic state of septic shock
and its important roles in cellular metabolism [21].
Thiamine might also reduce the risk of renal oxalate
crystallization by preventing the conversion of vitamin C
into oxalate, which is a potential adverse effect of vita-
min C administration [8].
Recently, several preliminary studies about the clinical
effects of vitamin C and thiamine have reported their re-
sults [22]. A phase I, randomized trial by Fowler et al.
[23] included placebo (n = 8), low-dose intravenous vita-
min C (50 mg/kg; n = 8), and high-dose vitamin C (200
mg/kg; n = 8); vitamin C reduced the levels of inflamma-
tory markers, including C-reactive protein (CRP) and
procalcitonin, in a dose-dependent manner in severe
sepsis and septic shock. In another small randomized
trial by Zabet et al. [24] involving 28 patients in the in-
tensive care unit (ICU), the mean dose and duration of
norepinephrine administration were significantly lower
in the treatment group receiving intravenous vitamin C
(100 mg/kg/day) than in the control group. Donnino et
al. evaluated the effects of thiamine in a two-centre, ran-
domized, double-blind trial in patients (n = 88) with sep-
tic shock. In the subgroup with thiamine deficiency
(35%), those in the thiamine treatment group had lower
lactate levels at 24 h and a decrease in mortality and the
rate of renal replacement therapy (RRT) [25, 26]. Woo-
lum et al. [27] used propensity matching in patients with
septic shock and found that thiamine supplementation
increased lactate clearance and decreased 28-day mortal-
ity. In a recently published before–after study (n = 94) by
Marik et al. [28], combination therapy of vitamin C,
thiamine, and steroid dramatically reduced mortality. A
similar before–after study by Kim et al. [29] used the
protocol from the study by Marik et al. and found a sig-
nificant reduction in mortality among patients with se-
vere pneumonia. However, these were both single-
centre, retrospective observational studies, and debate
remains about the effects of vitamin C and thiamine
supplementation.
The theoretical and experimental evidence published
to date suggests that vitamin C and thiamine supple-
mentation can be used as an adjunctive therapy for sep-
tic shock [30]. Vitamin C and thiamine have the
additional advantages of being inexpensive, widely avail-
able, and safe, with adverse effects occurring very rarely
[31]. Until recently, however, their potential role has not
been rigorously evaluated in a randomized clinical trial.
In this trial of the potential advantages of vitamin C and
thiamine, we hypothesize that their combined use will
reduce organ failure in patients with septic shock.
Objective
The Ascorbic Acid and Thiamine Effect in Septic Shock
(ATESS) trial is designed to evaluate the effects of early
combination therapy with intravenous vitamin C and
thiamine on recovery from organ failure, as indicated by
changes in the Sequential Organ Failure Assessment
(SOFA) score during the first 72 h in patients with septic
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shock. We will also evaluate whether this therapy im-
proves outcomes, including shock reversal and mortality,
in patients with septic shock.
Methods
Study design
This study is a randomized, double-blind, placebo-
controlled, multicentre trial in patients with septic shock.
It will be conducted in six emergency departments (EDs)
in South Korea. The trial protocol has been approved by
the Institutional Review Boards of the individual partici-
pating hospitals and the Ministry of Food and Drug Safety
in Korea. For all study participants, written informed con-
sent will be obtained from either the patient or from the
legal representative if the patient lacks capacity. Figures 1
and 2 show the study flow chart and the schedule, respect-
ively. A Standard Protocl Items: Recommandations for
Clinical Interventional Trials (SPIRIT) checklist is also
available (Additional file 1).
Eligibility criteria
Adult patients (19–89 years old) who visit an ED directly
and are diagnosed with septic shock will be included.
Septic shock is defined as sepsis with persisting
hypotension requiring vasopressors to maintain a mean
arterial pressure (MAP) ≥ 65 mmHg and with a serum
lactate level > 2 mmol/L despite adequate volume
resuscitation [2]. Sepsis is diagnosed in patients with
suspected infection and organ dysfunction, which is
identified as an acute change in the total SOFA score ≥ 2
points due to infection. If the baseline SOFA score is un-
known, it will be assumed to be 0.
The following exclusion criteria apply: patients who are
transferred from another hospital after vasopressor ad-
ministration or mechanical ventilatory support; patients
who have set limitations on treatment (e.g. patients with a
signed do-not-resuscitate order); patients with an under-
lying terminal-stage disease without an active treatment
plan and those who are not expected to survive to dis-
charge; patients taking at least 1 g/day of vitamin C or re-
ceiving intravenous thiamine prior to enrolment; patients
experiencing cardiac arrest prior to enrolment or who are
expected to die within 24 h despite best possible treat-
ment, based on the judgement of medical personnel; preg-
nant women; patients with glucose-6-phosphate
dehydrogenase deficiency; patients with a history of hyper-
sensitivity reactions to the trial drugs; patients with thalas-
semia; patients with hyperoxaluria; patients with
cystinuria; patients with ongoing gout attacks; patients di-
agnosed with oxalate renal stones; patients who meet the
inclusion criteria more than 24 h after ED arrival or who
are screened more than 24 h after their diagnosis of septic
shock; and patients who do not voluntarily consent to par-
ticipate in the trial (directly or by legal proxy).
Fig. 1 Study flow diagram
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Randomization and study medication
The patients will be randomly assigned in a 1:1 ratio to
either the treatment group or the placebo group. The
randomization sequence will be generated by an inde-
pendent biostatistician using a permuted block size of
four, stratified by recruitment site. The patients, treating
clinicians, and researchers will be blinded to the allo-
cated treatment throughout the trial. An identical num-
ber of ampoules of treatment drugs or placebo for each
patient will be packed in advance. The trial packs, which
contain the same number of ampoules of either vitamin
C (500 mg/2ml) and thiamine (50 mg/ 2 ml) or placebo
(0.9% saline, 2 ml), were identically manufactured by Jeil
Pharmaceutical (Daegu, South Korea). According to the
order of allocation, the sequential randomization code
for each site will be assigned to trial packs. When a pa-
tient in septic shock who meets the study criteria is
identified, written consent will be obtained, and a unique
randomization number will be assigned to each newly
included participant in the order of enrolment. The
treatment drug or placebo in the trial pack with the
same number will be administered to the participant.
For the treatment group, vitamin C (50 mg/kg, max-
imum single dose 3 g, daily dose 6 g) and thiamine (200
mg) will be mixed in a 50-ml 0.9% saline bag and admin-
istered through intravenous infusion over 60 min every
12 h for a total of 48 h. For the placebo group, an identi-
cal volume of 0.9% saline from the placebo drug am-
poule will be mixed in a 50-ml 0.9% saline bag and
administered with the same protocol. Vitamin C and the
placebo will be prepared in a sealed, opaque bag using a
light-protective infusion set. The researcher may request
unblinding of an independent pharmacist in the follow-
ing situations: suspected severe adverse effects, including
Fig. 2 Schedule of enrolment, interventions, and assessments. SOFA Sequential Organ Failure Assessment
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anaphylaxis, in which the researcher determines
unblinding to be necessary for the benefit and safety of
the patient; and when a patient or legal proxy requires
an investigation about suspected damage caused by par-
ticipation in the trial. Criteria for trial termination and
dropout are as follows: if a patient or legal proxy re-
quests termination of the trial or withdraws consent; if a
patient is transferred to another hospital within 5 days of
admission; if a patient or legal proxy does not follow the
instructions of the physician in charge of the trial; if a
patient develops a severe disease unrelated to participa-
tion in the trial; if the physician in charge of the trial de-
termines that participation in the trial is not the best
option for a given patient; and if a patient develops se-
vere adverse effects due to the test drug including
anaphylaxis.
Clinical management
Initial resuscitation and management will be performed
according to the latest Surviving Sepsis Campaign guide-
lines [32]. Broad-spectrum antibiotics will be adminis-
tered as soon as possible, and another general treatment,
such as source control, will be performed. Initially, 30
ml/kg of crystalloid fluids will be administered, but the
dose may be titrated up or down depending on the pa-
tient’s condition. If the patient shows no response to
fluids, norepinephrine will be administered to maintain a
MAP of at least 65 mmHg. For patients requiring high-
dose vasopressors (at least 0.2 μg/kg/min norepineph-
rine), additional vasopressin (0.03 U/min) and hydrocor-
tisone (200 mg/day: 50 mg every 6 h or 200mg over a
24-h continuous infusion) will be administered. Hydro-
cortisone will be administered until vasopressor therapy
is stopped, for up to 7 days. Once a patient reaches and
maintains the target MAP for at least 2 h, the dose of
norepinephrine will first be reduced (0.1 μg/kg/min per
hour) and then stopped completely, and the vasopressin
dose will be reduced by 0.01 U per hour. This will be
subject to modification based on the attending physi-
cian’s judgement and the patient’s status. Intravenous or
enteral nutrient supply will be implemented, including
the daily required amounts of vitamins to maintain nor-
mal nutrition. In cases in which vitamin C or thiamine
deficiency is suspected and the attending physician
judges it to be clinically necessary, open-label vitamin C
(500 mg/day) or thiamine (100 mg/day) will be adminis-
tered separately.
Data and laboratory measurements
All data will be anonymized and collected using web-
based report forms by investigators or trained research
coordinators at each participating hospital who are
blinded to the study group assignments. For quality con-
trol, data will be centrally reviewed at the coordinating
hospital. Adverse events will be recorded both prospect-
ively and by review of clinical charts (urticaria or rash,
anaphylaxis, vomiting, diarrhoea, gastrointestinal bleed-
ing, symptomatic nephrolithiasis, and others). Survival
data will be collected from visiting patients, hospital re-
cords, and telephone interviews. Blood samples will be
collected at enrolment prior to study drug administra-
tion and 72 h after enrolment for use in laboratory tests:
complete blood count, creatinine, lactate, CRP, procalci-
tonin, vitamin C level, and thiamine level. We plan to
collect and store serum samples at the same time. These
samples will be stored for future biomarker analysis.
Outcome measure
The primary outcome will be the ΔSOFA score, which is
a 72-h change in SOFA score that reflects recovery from
organ failure (ΔSOFA = initial SOFA at enrolment –
follow-up SOFA after 72 h) [28, 33]. If a patient dies in
the first 72 h, the previous worst score will be used. Sec-
ondary outcomes will be mortality (7-day, 28-day, 90-
day, in-hospital, ICU death), time to death, time to
shock reversal, vasopressor-free days, dose of vasopres-
sor (at 24, 48, and 72 h from enrolment and maximum
dose during 72 h), ventilator-free days, ventilator dur-
ation, RRT-free days, new use of RRT, new onset or ag-
gravation of acute kidney injury (AKI), length of ICU
stay, ICU-free days, length of hospital stay, CRP change
during the initial 72 h (%), and procalcitonin change dur-
ing the initial 72 h (%). For CRP and procalcitonin, if a
patient dies within the first 72 h, the last follow-up
values will be used. Shock reversal is defined as discon-
tinuation of all vasopressors and MAP maintained at 60
mmHg or more for longer than 24 h [34]. For outcome
variables showing free days, the time frame will be from
enrolment day to day 14. If a patient dies before day 14,
the free days after death will be considered 0. The dose
of vasopressor is expressed as a norepinephrine equiva-
lent dose [35]. AKI is defined as Kidney Disease: Im-
proving Global Outcomes (KDIGO) stage 2 or higher,
which is new-onset change [36]. For evaluation of the
KDIGO stage, baseline creatinine is derived from the
lowest value from 1 year to 24 h prior or estimated by a
predefined formula (creatinine = 0.74–0.2 (if female) +
0.003 × age) if the former is unavailable [37]. Patients re-
ceiving dialysis for chronic end-stage renal failure will be
excluded from the analysis.
Statistical analysis
The sample size was calculated based on the ΔSOFA
score. With reference to the ΔSOFA scores of a control
group in a study by Marik et al. [28], we anticipate the
mean and standard deviations of the ΔSOFA scores in
the control group to be 1.0 and 2.7, respectively, and the
mean ΔSOFA score in the test group to be at least 2.5.
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This effect size of a 1.5-point improvement in the 72-h
SOFA score is set as a surrogate value for a survival
benefit in patients. Assuming that the standard deviation
of the ΔSOFA score is the same in both groups, with a
statistical significance of 5% and power of 80%, the re-
quired participant number per group is 52 patients. As-
suming a dropout rate of 10%, we determined that 58
patients will be required in each group (total n = 116).
Data analyses will be conducted with the intention-to-
treat set, the full analysis set, and the per-protocol ana-
lysis set, and missing data will not be imputed. For the
primary outcome analysis, the ΔSOFA scores will be
compared using t tests or the Mann–Whitney test, de-
pending on the distribution between the two groups. For
secondary outcomes and adverse events, we will use t
tests or the Mann–Whitney test for continuous variables
and the chi-square test or Fisher’s exact test for categor-
ical variables. Linear mixed models and generalized lin-
ear mixed models will be used for multivariable analyses
of continuous outcomes and categorical outcomes, re-
spectively, adjusting for study centre (random effect)
and the covariates (fixed effect) of age, sex, infection
foci, underlying disease, SOFA score, initial lactase level,
and albumin level, if the covariates are unbalanced be-
tween the test group and the control group. Survival
duration and time to shock reversal will be analysed
using the Kaplan–Meier method and compared by the
log-rank test. Subgroup analysis will be conducted by
predefined groups according to age, sex, infection site,
norepinephrine dose at randomization, SOFA score, hy-
poalbuminemia, adjunctive steroid use, time from
hypotension to trial drug administration, malignancy,
vitamin C level, and thiamine level. P < 0.05 will be con-
sidered statistically significant and corrected using Bon-
ferroni’s method for multiple testing. Statistical analysis
will be performed using SAS version 9.4 (SAS Institute,
Cary, NC, USA) and STATA version 15.1 (STATA Cor-
poration, College Station, TX, USA). A data monitoring
committee will be established to review trial data upon
recruiting half of the planned patients. This will consist
of an independent physician who is experienced with
clinical trial implementation and a biostatistician. The
committee will evaluate differences in the primary out-
come to decide whether the researcher terminates the
trial or continues, and will assess adverse events.
Discussion
Treatment of septic shock is challenging, and mortality
is high despite maximal intensive care [6]. Moreover,
most clinical trial interventions for septic shock have
failed to improve outcomes, so the development of ef-
fective treatments is important [7]. Vitamin C and
thiamine are potential candidates for adjunctive therapy
for septic shock. These are safe treatments expected to
improve prognosis based on recent experimental and
clinical studies [8]. The key goal of this study is to assess
the effects of early combination therapy with intravenous
vitamin C and thiamine on recovery from organ failure
in patients with septic shock. This trial, along with
current ongoing trials [30], will provide important evi-
dence about the effectiveness of vitamin C and thiamine
supplementation for septic shock when administered
early in the ED. If this therapy is shown to be effective,
this regimen would be immediately applicable to the
management of septic shock and could become one of
the main therapeutic adjuncts.
In this trial, we have chosen the ΔSOFA score as the
primary endpoint. A relatively large number of patients
would be required to evaluate a survival difference. The
ΔSOFA score is well correlated with survival and reflects
recovery from organ failure [33, 38, 39]. Therefore, this
primary outcome measurement might be a reasonable
approach to complement the limitation of a relatively
small sample size. In addition, we will measure several
important secondary endpoints, including mortality and
shock reversal time.
Steroid use can reduce the duration of vasopressor use
and enhance recovery from shock, although there is no
definite evidence that it improves survival [34]. Steroids
can be used with vitamin C for synergistic effects, and
other trials have proposed this combination [28, 30, 40].
In this trial, we will add steroid treatment only for pa-
tients requiring a high dose of vasopressor, in accord-
ance with the current Surviving Sepsis Campaign
guidelines [32]. We will perform subgroup analyses ac-
cording to concomitant use of a steroid, which might
provide data about potential treatment synergism.
Regarding vitamin C and thiamine use for septic shock
patients, the pharmacokinetics, optimal dosage, and dur-
ation need to be investigated [22]. In addition to the clinical
outcomes, this trial will allow us to evaluate the effects of
vitamin C and thiamine supplementation during the initial
48-h period in septic shock, which has higher metabolic de-
mands, on blood levels of vitamin C and thiamine.
Trial status
Currently recruiting. Trial start date was 1 December
2018. Anticipated recruitment end date is December
2019.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 125 kb)
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